27.08.2020

Sechenov University achievements marked by QS magazine

Sechenov University achievements marked by QS magazine The leading publisher in higher education worldwide notices the research and innovation at Sechenov.

Sechenov University continues to confirm its exceptional position among medical universities of Russia. The latest activities of the University have attracted attention from widely recognised international organisations, such as QS (Quacquarelli Symonds), a major publisher of a series of magazines on higher education and research. Sechenov’s participation in the clinical trial of Russia’s first vaccine against COVID-19 has been reported in the latest issue of QS Global Education News (QS-GEN), a quarterly newsletter which highlights faculty accomplishments, research breakthroughs, and innovations that take place at universities across the globe.

Apart from the vaccine trial, Sechenov is also testing a number of potential drugs against the coronavirus disease, including favipiravir, levilimab, and elsulfavirine. Some of these substances were previously used for the treatment of other conditions, for example, arthritis and HIV. Within the last one and a half years, Sechenov conducted 25 pre-clinical studies and 27 clinical trials overall.

The full article in the QS-GEN can be found via the link.